About E3 ubiquitin-protein ligase rififylin
E3 ubiquitin-protein ligase rififylin (RFFL) is a protein
from Homo sapiens identified by UniProt accession
Q8WZ73, 363 residues long.
MolForge cross-references it against 0 known binders and
52 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase rififylin |
|---|
| UniProt accession | Q8WZ73 |
|---|
| Gene | RFFL |
|---|
| Organism | Homo sapiens |
|---|
| Length | 363 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (52)
Diseases linked to this target (Open Targets).
- electrocardiography · score 0.26
- breast adenocarcinoma · score 0.26
- lung adenocarcinoma · score 0.23
- head and neck squamous cell carcinoma · score 0.23
- gastric adenocarcinoma · score 0.23
- QT interval · score 0.19
- pulse pressure measurement · score 0.17
- TPE interval measurement · score 0.15
- neurofibrillary tangles measurement · score 0.15
- sex hormone-binding globulin measurement · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8WZ73-F1 | alphafold | PREDICTED | 71.39 | — |
Amino-acid sequence (363 residues)
MWATCCNWFC LDGQPEEVPP PQGARMQAYS NPGYSSFPSP TGLEPSCKSC GAHFANTARK QTCLDCKKNF CMTCSSQVGN GPRLCLLCQR FRATAFQREE LMKMKVKDLR DYLSLHDIST EMCREKEELV LLVLGQQPVI SQEDRTRAST LSPDFPEQQA FLTQPHSSMV PPTSPNLPSS SAQATSVPPA QVQENQQANG HVSQDQEEPV YLESVARVPA EDETQSIDSE DSFVPGRRAS LSDLTDLEDI EGLTVRQLKE ILARNFVNYK GCCEKWELME RVTRLYKDQK GLQHLVSGAE DQNGGAVPSG LEENLCKICM DSPIDCVLLE CGHMVTCTKC GKRMNECPIC RQYVIRAVHV FRS
Explore E3 ubiquitin-protein ligase rififylin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets